Serological and genetic analysis of a B3 phenotype caused by c. 259G > T in the ABO gene
Transfusion Medicine · 2025
DOI: 10.1111/tme.13140 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transfusion Medicine, 2025. Verfasst von Min Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion Medicine, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China. Hauptthemen laut MEDLINE: ABO Blood-Group System, Alleles, Point Mutation, Mutation, Missense. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Changsha Science and Technology Bureau, Changsha, Hunan Province, China.
Abstract (Originalsprache)
Background
Mixed agglutination is a serological pattern in some ambiguous ABO blood type identification. This study focused on the serological and molecular genetic characteristics of a B3 phenotype induced by a c.259G > T mutation in the ABO gene. Study Design and Methods Serological methods such as gel cards and tubes were used to identify the ABO blood type of the patient, with fluorescent PCR for ABO genotyping and Sanger sequencing for analysing the ABO exons. Protein 3D Structure was simulated and further analysed using SWISS‐MODLE and PyMOL. Both the wild‐type (VAL‐87, ABO*B.01 ) and the mutant (p.Val87Leu) plasmids were transfected into Hela cells to assess the agglutination intensity of the transfected cells with anti‐B antibodies.
Results
Serological testing showed weak expression of the B antigen and mixed agglutination with anti‐B antibodies. ABO genotyping indicated the presence of a B allele, but exon sequencing revealed an additional c.259G > T mutation in exon 6 based on the ABO*B.01 allele. The simulated three‐dimensional structures of the proteins showed increased steric hindrance with mutations, leading to a relatively loose structure. The transfected Hela cells with the mutant (p.Val87Leu) plasmid exhibited a significantly reduced agglutination intensity with anti‐B antibodies.
Conclusion
Based on comprehensive serological, genetic, and simulation analyses, it is concluded that the c.259G > T mutation in exon 6 of the ABO*B.01 allele results in an amino acid change within the enzymatic active site. This alteration likely impacts protein stability and reduces B antigen expression, leading to the B3 subtype phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Transfusion Medicine, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China.
- Blood Transfusion Institute, Jiangsu Zojiwat Biopharmaceutical Co., Ltd., Wuxi, China.
- Emergency Research Institute, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China.
- Department of Transfusion Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
ORCID-Profile: Min Zhang, Hongjun Gao
Förderung
- Changsha Science and Technology Bureau, Changsha, Hunan Province, China
Zitieren
APA
Zhang, M., Gao, H., Jiang, Y., Liu, F., Huan, X., Huang, Z., Yuan, F., & Lei, P. (2025). Serological and genetic analysis of a B3 phenotype caused by c. 259G > T in the ABO gene. Transfusion Medicine. https://doi.org/10.1111/tme.13140
Vancouver
Zhang M, Gao H, Jiang Y, Liu F, Huan X, Huang Z, et al. Serological and genetic analysis of a B3 phenotype caused by c. 259G > T in the ABO gene. Transfusion Medicine. 2025. doi:10.1111/tme.13140
BibTeX
@article{Zhang2025,
author = {Zhang, Min and Gao, Hongjun and Jiang, Yu and Liu, Fengxia and Huan, Xisha and Huang, Zhen and Yuan, Fen and Lei, Ping},
title = {Serological and genetic analysis of a B3 phenotype caused by c. 259G > T in the ABO gene},
journal = {Transfusion Medicine},
year = {2025},
doi = {10.1111/tme.13140}
}
EUVIMED